Twist Bioscience Corporation stocks have been trading up by 16.21 percent following upbeat news on its synthetic biology progress
Click Here for a Millionaire's POV on Trading TWST
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Leerink raised its price target on Twist Bioscience from $120 to $160 and kept an Outperform rating, pointing to a big AI drug discovery opportunity.
- The company will supply antibody characterization data and services into Lilly’s AI/ML TuneLab platform, plugging its wet-lab workflows into Lilly’s discovery models.
- Shares climbed more than 4% after the Lilly TuneLab announcement, signaling traders’ enthusiasm for TWST’s AI deal flow.
- Management said Anthropic-related mini-binder work is real but already baked into fiscal 2027 orders guidance.
- A recent Form 4 showed changes in beneficial ownership of Twist Bioscience stock by an insider or major holder.
Live Update At 16:46:56 EDT: On Thursday, September 24, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 16.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Twist Bioscience, trading under ticker TWST, has been on a sharp run. From late August to late September 2026, TWST climbed from around $139 to a close near $184, a move that shows clear upside momentum on the daily chart. That’s a strong trend, not just noise.
The intraday tape on the latest session backs this up. TWST opened near $158 and pushed as high as about $185 before closing just above $184. That’s a wide intraday range with buyers in control into the close, a classic sign of aggressive accumulation. For active traders, this is what a strong trend day looks like.
More Breaking News
- NCPL Stock Jumps As Traders Target Volatile Breakout
- Oracle Stock Slides As Layoffs And Credit Worries Rattle Traders
- APUS Stock Explodes Higher As Traders Target Volatile Breakout
- UXIN Stock Rides Asian ADR Rally As Momentum Builds
Fundamentally, Twist Bioscience is still a high-growth, loss-making name. Quarterly revenue sits around $118.4M with gross margin near 52%, but EBIT margin is roughly -31.8% and net income was about -$35.1M for the recent quarter. TWST trades at a rich price-to-sales multiple over 25x and a price-to-book near 24x. At the same time, the balance sheet shows cash and short-term investments of roughly $166.8M and a current ratio of 2.7, giving Twist Bioscience some breathing room to keep funding growth while it chases AI-driven bio opportunities.
Why Traders Are Watching TWST
Traders are locked in on TWST right now because the story lines up: strong chart, real news, and a clear AI angle. The Lilly TuneLab agreement is the centerpiece. Twist Bioscience will provide antibody characterization data and services directly into Eli Lilly’s AI/ML drug discovery platform. In simple terms, TWST runs the wet lab, Lilly runs the AI, and both sides want to speed up antibody drug discovery.
That matters because data is the fuel for any AI model. By channeling Twist Bioscience’s preferred antibody protocols and high-quality lab data into Lilly’s systems, TWST is positioning itself as a key infrastructure player in AI biologics. This is not a one-off product sale; it looks more like a recurring data-services pipeline tied to large pharma R&D budgets.
The market reaction confirms the importance. Multiple reports note Twist Bioscience shares jumped, at one point more than 4%, after the Lilly TuneLab news hit. Traders are rewarding AI-linked, big-pharma collaborations, and TWST now has one with a marquee name.
Layer on top the fresh Leerink call: an Outperform rating and a price target boost from $120 to $160. That’s a meaningful hike even after TWST’s big move higher, and it signals that at least one major Wall Street shop thinks Twist Bioscience’s revenue guidance is conservative given the early-stage AI drug discovery opportunity. For momentum traders, that kind of external validation often keeps the squeeze going.
There’s also the Anthropic angle. TWST confirmed pilot work on AI-designed mini-binder proteins for the AI company is already “probably sort of” included in fiscal 2027 orders. So it’s real business, but management is clear it’s not hidden upside vs current guidance. That helps keep expectations grounded.
Conclusion
Twist Bioscience is trading like a classic high-beta growth name tied to a hot theme. TWST’s chart shows a near-vertical climb from the $130s to the $180s in under a month, backed by real catalysts: the Eli Lilly TuneLab agreement, an expanded role feeding antibody characterization data into AI models, and a bullish price-target raise from Leerink to $160 with an Outperform stance.
At the same time, the financials remind traders what TWST is: a company with strong revenue growth and 52% gross margins, but still posting quarterly net losses above $35M and negative returns on equity and assets. The balance sheet, with over $100M in cash and a manageable debt load, gives Twist Bioscience time to execute on these AI and pharma partnerships. A recent Form 4 filing shows insider ownership is active, which many traders monitor as part of their due diligence, even if the filing itself is routine.
For active traders, TWST now sits at the intersection of biotech and AI — exactly where speculation loves to cluster. The key is to treat it like a trade, not a hope. As Tim Sykes always says, “Trade the price action, not the hype.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.”. TWST’s price action is hot right now, and that’s where disciplined chart study, tight risk management, and a plan to cut losses fast really matter. This analysis is for educational and research purposes only, but it lays out why Twist Bioscience has earned a front-row seat on many trading screens.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.